Skip to main content
Equibles

MARKSANS · Marksans Pharma Limited · Financials

Use MARKSANS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MARKSANS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
318.50 INR -1.50 (-0.47%) At close · Nov 13
Rebalance outlook locked
Market Cap
144.37B INR
Shares
453.29M
Volume · Nov 13 1.75M Avg daily vol (3M) 2.43M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
29.51B +1025.1%
FY2026 Revenue FY2018–FY2026
Net Income
4.18B
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
4.58B +2116.8%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
INR 33.92B 29.51B 2.62B 21.77B 18.52B 14.91B 13.76B 11.34B 10B 7.67B
INR 1.06B 986.32M 83.39M 742.7M 518.53M 447.76M 361.51M 266.62M 228.04M 300.93M
INR 260.75M 241.25M 11.66M 112.03M 91.28M 84.46M 79.86M 87.46M 96.55M 67.75M
INR 7.51B 5.61B 503.97M 4.24B 3.38B 2.48B 3.02B 1.57B 1.04B 148.98M
INR 1.85B 1.4B 121.35M 1.09B 723.32M 606.97M 636.26M 364.19M 238.7M 35.63M
INR 5.6B 4.18B 0 3.43B 2.65B 1.87B 2.39B 1.21B 760.63M 113.35M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 826.22M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.